Search Browse Earnings

89bio, Inc. — SlamSEC

89bio, Inc.

Pharmaceutical Preparations·SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$102.2M

FY 2024

Net Income

-$102.0M

FY 2024

EPS (Diluted)

-$2.93

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$316.2M

FY 2024

Total Debt

$24.8M

FY 2024

Net Cash

$291.4M

FY 2024

Enterprise Value

—

Debt / EBITDA

2.9x

FY 2024

EV / EBITDA

—

Employees

—